Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, Katlama C, Slama L, Liegeon G, Beniguel L, Ohayon M, Mouhim H, Goldwirt L, Spire B, Loze B, Surgers L, Pavie J, Lourenco J, Ben-Mechlia M, Le Mestre S, Rojas-Castro D, Costagliola D; ANRS PREVENIR Study Group. Molina JM, et al. Among authors: slama l. Lancet HIV. 2022 Aug;9(8):e554-e562. doi: 10.1016/S2352-3018(22)00133-3. Epub 2022 Jun 27. Lancet HIV. 2022. PMID: 35772417
[HIV vaccines].
Pialoux G, Slama L. Pialoux G, et al. Among authors: slama l. Presse Med. 2005 Nov 19;34(20 Pt 2):1592-6. doi: 10.1016/s0755-4982(05)84231-9. Presse Med. 2005. PMID: 16314820 Review. French.
Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.
Pialoux G, Hocini H, Pérusat S, Silberman B, Salmon-Ceron D, Slama L, Journot V, Mathieu E, Gaillard C, Petitprez K, Launay O, Chêne G; ANRS VAC14 Study Group. Pialoux G, et al. Among authors: slama l. Vaccine. 2008 May 19;26(21):2657-66. doi: 10.1016/j.vaccine.2007.11.002. Epub 2007 Nov 26. Vaccine. 2008. PMID: 18068876 Clinical Trial.
Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.
Pialoux G, Quercia RP, Gahery H, Daniel N, Slama L, Girard PM, Bonnard P, Rozenbaum W, Schneider V, Salmon D, Guillet JG. Pialoux G, et al. Among authors: slama l. Clin Vaccine Immunol. 2008 Mar;15(3):562-8. doi: 10.1128/CVI.00165-07. Epub 2008 Jan 9. Clin Vaccine Immunol. 2008. PMID: 18184824 Free PMC article. Clinical Trial.
Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team. Valantin MA, et al. HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8. HIV Med. 2008. PMID: 18624724 Free article. Clinical Trial.
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
185 results